Phase 4 N=533 Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B
Chronic Hepatitis B
Primary: Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104 — 85; 403 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=128 A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Hepatitis B, Chronic
Primary: Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period — 11.8; 25.0; 20.0 percentage of participants — p=0.08
Phase 2 N=170 Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen
Chronic Hepatitis B
Primary: Difference in Percentage of Patients Between Treatment and Comparator Arm Reaching a ≥ 1log10 Decline of Quantitative HBsAg After 48 Weeks — 26; 1; 80; 53 Participants…
Phase 4 N=241 Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Chronic Hepatitis B
Primary: Percentage of Participants Achieving HBV DNA < 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) - — 91.0; 95.0; 91.9; 95.0 percentage of participants
N/A N=141 An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants With Suppression of HBV DNA to < 2,000 IU/ml at the End of the Study — 38.8 Percentage of participants
Phase 2 N=48 Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
Chronic Hepatitis B
Primary: Proportion of Patients With HBsAg Response at 12 Week of Therapy — 0; 0; 1; 0 Participants
Phase 4 N=43 Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Chronic Hepatitis B
Primary: Proportion of Participants With HBsAg Loss at Week 144 in Both Study Arms — 0.236; 0 Proportion of participants — p=0.022
Phase 4 N=24 A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Hepatitis B, Chronic
Primary: Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL) — 7 participants
Phase 4 N=39 A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Number of Hepatitis B Envelope Antigen (HBeAg) Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Less Than (<) 1,00,000 Copies Per Milliliter…
Phase 1 N=20 Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg
Chronic Hepatitis B
Primary: Change in HBsAg Levels From Baseline to 2 Years — -0.27 log IU/ml — p=<0.05
Phase 4 N=197 Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Hepatitis B, Chronic
Primary: Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240 — 6.045 Events per person-year
Phase 2 N=76 A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression
Hepatitis B, Chronic
Primary: Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48) — 59.13 percent change
Phase 4 N=383 A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Envelope Antigen (HBeAg) Seroconversion. — 9.7; 14.6; 19.8; 31.6 Percentage of participants
Phase 2 N=51 Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
Chronic Hepatitis B
Primary: Mean Change in Quantitative Hepatitis B Surface Antigen (qHBsAg) — 0.0; 0.0; 0.0; 0.0 log10 IU/mL — p=1.000
N/A N=160 Study of Telbivudine in Chronic Hepatitis B
Chronic Hepatitis B
Primary: HBV-DNA < 300 Copies/mL in 48 Weeks — 79 participants
Phase 2 N=12 A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
Hepatitis B
Primary: Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ) — 25 Percentage of participants
Phase 3 N=382 A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
Chronic Hepatitis B
Primary: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell…
Phase 2 N=13 Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
Chronic Hepatitis B
Primary: Change in Interferon-stimulated-gene (ISG) Expression — -2.716; 1.670; -2.20; -1.597 log 2 fold change
Phase 4 N=150 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72 — 20.9; 21.9 percentage of participants
Phase 3 N=201 Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
Hepatitis B
Primary: Percent of Participants With Hepatitis B Surface Antigen (HBsAg) Loss by Week 240 — 4.1; 5.2 Percentage of participants — p=0.72
Phase 2 N=21 Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
Hepatitis B
Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…
Phase 4 N=120 A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection
Chronic Hepatitis B
Primary: Percentage of Participants Who Achieved a Virologic Response at Week 24 — 92.86; 67.19 Percentage of participants — p=0.0006
Phase 2 N=54 A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B, Chronic
Primary: Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping All Study Interventions at the End of…
Phase 3 N=671 PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
Hepatitis B, Chronic
Primary: Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss — 39; 40; 70 Participants — p=0.860
Phase 3 N=166 Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
Hepatitis B, Chronic
Primary: Mean Change From Baseline in Serum HBV DNA Level at Week 24 — -4.63; -4.50 log10 copies/milliliter (copies/mL) — p=<0.0001
Phase 4 N=197 A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Envelope Antigen Seroconversion at Week 48 — 14.89; 6.12 Percentage of participants
Phase 2 N=24 Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
Chronic Hepatitis D Infection
Primary: Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy — 0; 0; 0 Participants
Phase 3 N=62 A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
Pediatric Immuno-Tolerant Chronic Hepatitis B
Primary: Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation — 3.8; 0 Percentage of…
Phase 2 N=24 A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
Hepatitis B
Primary: Panel 1 and 2: Absolute Change From Baseline in the Percentage of Hepatitis B Surface Antigen (HBsAg) Hepatocytes at Week 40 — -78.46; -5.68 percentage of HBsAg…
N/A N=12,378 Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Chronic Hepatitis B
Primary: Number of Participants With Adjudicated Overall Malignant Neoplasms — 331; 337 Participants — p=0.3553